In these challenging times, our mission has never been clearer: optimizing and enabling patient access with evidence of product value, effectiveness, and safety.
We are Joining You in the COVID-19 Fight
Our Work in Action
Medimix Oncology Survey
A special LiveTracker™ survey was created asking oncologists how the COVID-19 pandemic is affecting their practice and how they are using telemedicine to allow patients to stay home and balance the risk of delayed interventions with the danger of contracting COVID-19. First results are in from 600 oncologists across the EU5 and the US!
The Medimix team has implemented improvements that will allow clients to track patients’ COVID-19 status across all LiveTracker offerings. This will allow clients to evaluate the impact of COVID-19 on biopharmaceutical usage and changes in treatment patterns.
Virtual Expanded Access Program
We were able to provide a virtual approach to mitigate the risk to patient safety in the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability. First patient to be dosed within one month of start.
NHS England Model to Predict Hospital Capacity
The Guy’s and St Thomas’ NHS Foundation Trust, part of the English National Health Service, asked the London School of Economics (LSE) for help building a model of a hospital facing increasing COVID-19 cases to help determine when their capacity would be exceeded and by how much. LSE asked Evidera’s J. Jaime Caro, a Professor in Practice, to help with this project, and he and Jörgen Moller have constructed a DICE simulation that responds to their needs. In the process, they also developed some new methods to address this challenging problem. The model will be used by the NHS trusts as needed and published as open source.
Using FLU-PRO© to Quantify Symptoms of COVID-19
The symptomatic manifestations of COVID-19 and the effects of treatment on symptomatic relief and recovery are not well understood.
The InFLUenza Patient-Reported Outcome (FLU-PRO) is a comprehensive measure that should be considered for studies of COVID-19.